EIMEAR P. BONNER - 27 Feb 2026 Form 4 Insider Report for CHEVRON CORP (CVX)

Role
Chief Financial Officer
Signature
/s/ Rose Z. Pierson, Attorney-in-Fact for Eimear P. Bonner
Issuer symbol
CVX
Transactions as of
27 Feb 2026
Net transactions value
-$1,149,431
Form type
4
Filing time
03 Mar 2026, 18:25:12 UTC
Previous filing
12 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BONNER EIMEAR P Chief Financial Officer 1400 SMITH STREET, HOUSTON /s/ Rose Z. Pierson, Attorney-in-Fact for Eimear P. Bonner 03 Mar 2026 0001880440

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVX Common Stock Options Exercise $2,864,180 +18,800 +223% $152.35 27,228 27 Feb 2026 Direct F1, F2
transaction CVX Common Stock Options Exercise $1,470,912 +9,600 +35% $153.22 36,828 27 Feb 2026 Direct F1
transaction CVX Common Stock Sale $1,013,527 -5,500 -15% $184.28 31,328 27 Feb 2026 Direct F1, F3
transaction CVX Common Stock Sale $463,334 -2,500 -8% $185.33 28,828 27 Feb 2026 Direct F1, F4
transaction CVX Common Stock Sale $3,376,745 -18,100 -63% $186.56 10,728 27 Feb 2026 Direct F1, F5
transaction CVX Common Stock Sale $430,469 -2,300 -21% $187.16 8,428 27 Feb 2026 Direct F1, F6
transaction CVX Common Stock Options Exercise $3,115,992 +17,400 +206% $179.08 25,828 02 Mar 2026 Direct F1
transaction CVX Common Stock Sale $3,316,440 -17,400 -67% $190.60 8,427 02 Mar 2026 Direct F1
holding CVX Common Stock 408 27 Feb 2026 Share Incentive Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CVX Non-Qualified Stock Option (Right to Buy) Options Exercise $0 -18,800 -67% $0.000000 9,400 27 Feb 2026 Common Stock 18,800 $152.35 Direct F7
transaction CVX Non-Qualified Stock Option (Right to Buy) Options Exercise $0 -9,600 -33% $0.000000 19,200 27 Feb 2026 Common Stock 9,600 $153.22 Direct F8
transaction CVX Non-Qualified Stock Option (Right to Buy) Options Exercise $0 -17,400 -100% $0.000000 0 02 Mar 2026 Common Stock 17,400 $179.08 Direct F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2025.
F2 This number includes rounding of fractional shares.
F3 This transaction was executed in multiple trades at prices ranging from $183.85 to $184.82, inclusive. The price reported in Column 4 reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (6) to this Form.
F4 These shares were sold in multiple transactions at prices ranging from $184.85 to $185.83, inclusive. The price reported in Column 4 reflects the weighted average sale price.
F5 These shares were sold in multiple transactions at prices ranging from $185.87 to $186.85, inclusive. The price reported in Column 4 reflects the weighted average sale price.
F6 These shares were sold in multiple transactions at prices ranging from $186.95 to $187.43, inclusive. The price reported in Column 4 reflects the weighted average sale price.
F7 Option granted 2/6/2024. One-third of the shares subject to the option vested on February 10, 2025 and February 10, 2026, respectively, and one-third of the shares will vest on February 10, 2027.
F8 Option granted 2/4/2025. One-third of the shares subject to the option vested on February 10, 2026 and one-third of the shares will vest on February 10, 2027 and February 10, 2028, respectively.
F9 Option granted 1/25/2023. One-third of the shares subject to the option vested on January 31, 2024, January 31, 2025 and January 31, 2026, respectively.